Inhibiting or antagonizing glucagon: Making progress in diabetes care

Diabetes, Obesity and Metabolism

Volumn 17, Issue 8, 2015, Pages 720-725

  Lefebvre P J ^a   Paquot, N ^a   Scheen, A J ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Diabetes; Glucagon

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALBIGLUTIDE; ALOGLIPTIN; ALPHA GLUCOSIDASE INHIBITOR; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EMPAGLIFLOZIN; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON RECEPTOR; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; MONOCLONAL ANTIBODY; RECEPTOR ANTIBODY; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNINDEXED DRUG; VILDAGLIPTIN; VOGLIBOSE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSIDASE INHIBITOR; SULFONYLUREA DERIVATIVE;

DIABETES MELLITUS; FATTY LIVER; GLUCAGON RELEASE; HUMAN; HYPERGLUCAGONEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LIVER CELL DAMAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET CELL HYPERPLASIA; PATHOPHYSIOLOGY; PATIENT CARE; REVIEW; RODENT MODEL; SIGNAL TRANSDUCTION; AGONISTS; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; METABOLISM; PANCREAS; SECRETION (PROCESS);

DIABETES MELLITUS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG-INDUCED LIVER INJURY; GLUCAGON; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-SECRETING CELLS; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; PANCREAS; SIGNAL TRANSDUCTION; SULFONYLUREA COMPOUNDS;

EID: 84937816467     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12480     Document Type: Review

References (90)

1. Lefèbvre P. Glucagon's golden jubilee at the University of Liège. Br J Diabetes Vasc Dis 2012; 12: 278-284.
2. Lefèbvre PJ, Luyckx AS. Glucagon and diabetes: a reappraisal. Diabetologia 1979; 16: 347-354.
3. Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci U S A 2010; 107: 16009-16012.
4. Lefèbvre PJ (ed). Glucagon I and II (Handbook of Experimental Pharmacology), Vol. 66, Vols I and II. Berlin: Springer, 1983.
5. Lefèbvre PJ (ed). Glucagon III (Handbook of Experimental Pharmacology), Vol. 123. Berlin: Springer, 1996.
6. Cerasi E, Accili D, Ahrén B, Henquin J-C, Seino S (eds). Pancreatic α-cells and glucagon - Neglected metabolic actors. Diabetes Obes Metab 2011; 13(Suppl. 1): 166.
7. Lefèbvre PJ. Glucagon and diabetes. In: Lefèbvre PJ, (ed). Glucagon III (Handbook of Experimental Pharmacology), Vol. 123. Berlin: Springer, 1996; 115-131.
8. Edgerton DS, Cherrington AD. Glucagon as a critical factor in the pathology of diabetes. Diabetes 2011; 60: 377-380.
9. Dinneen S, Alzaid A, Turk D, Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 1995; 38: 337-343.
10. Fredhelm S, Andersen M-L, Pörksen S etal. The influence of glucagon on postprandial hyperglycemia in children 5 years after onset of type 1 diabetes. Diabetologia 2015; 58: 828-834.
11. Paquot N, Schneiter P, Jéquier E etal. Effects of ingested fructose and infused glucagon on endogenous glucose production in obese NIDDM patients, obese non-diabetic subjects, and healthy subjects. Diabetologia 1996; 39: 580-586.
12. Shah P, Vella A, Basu A, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with Type 2 diabetes mellitus. J Clin Endocrinol Metab 2000; 85: 4053-4059.
13. Greenbaum CJ, Prigeon RL, D'Alessio DA. Impaired β-cell function, incretin effect, and glucagon suppression in patients with Type 1 diabetes who have normal fasting glucose. Diabetes 2002; 51: 951-957.
14. Ipp E. Impaired glucose tolerance. The irrepressible α-cell? Diabetes Care 2000; 23: 569-570.
15. Larsson H, Ahrén B. Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in post-menopausal women with impaired glucose tolerance. Diabetes Care 2000; 23: 650-657.
16. Choukem SP, Sobngwi E, Boudou P etal. Beta- and alpha-cell dysfunction in Africans with ketosis-prone atypical diabetes during near-normoglycemic remissions. Diabetes Care 2013; 36: 118-123.
17. Lefèbvre P. Ketosis-prone atypical diabetes: glucagon there, too. Diabetes Care 2013; 36: 8-10.
18. Henquin JC, Rahier J. Pancreatic alpha cell mass in European subjects with type 2 diabetes. Diabetologia 2011; 54: 1720-1725.
19. Samols E, Weir GC, Bonner-Weir S. Intra-islet insulin- glucagon-somatostatin relationships. In: Lefèbvre PJ, ed. Glucagon, Vol. II. Berlin: Springer, 1983; 133-173.
20. Lefèbvre P, Paolisso G, Scheen AJ. Pulsatility of glucagon. In: Lefèbvre PJ, ed. Glucagon III (Handbook of Experimental Pharmacology). Berlin: Springer, 1996; 105-113.
21. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 2012; 122: 4-12.
22. Bosco D, Armanet M, Morel P etal. Unique arrangement of α- and β-cells in human islets of Langerhans. Diabetes 2010; 59: 1202-1210.
23. Lefèbvre P. Diabetes as a paracrinopathy of the islets of Langerhans. Eur Endocrinol 2011; 7: 79-82.
24. Meier JJ, Kjems LL, Veldhuis JD etal. Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis. Diabetes 2006; 55: 1051-1556.
25. Menge BA, Grüber L, Jørgensen SM etal. Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes. Diabetes 2011; 60: 2160-2168.
26. Yu X, Park BH, Wang MY etal. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci U S A 2008; 105: 14070-14075.
27. Lee Y, Wang M-Y, Du XQ etal. Glucagon receptor knock out prevents insulin-deficient type 1 diabetes in mice. Diabetes 2011; 60: 391-397.
28. Jun LS, Millican RL, Hawkins ED etal. Absence of glucagon and insulin action reveals a role for Glucagon-like Peptide-1 receptor in endogenous glucose production. Diabetes 2015; 64: 819-827.
29. Lee Y, Berglund ED, Wang MY etal. Metabolic manifestations of insulin deficiency do not occur without glucagon action. Proc Natl Acad Sci U S A 2012; 109: 14972-14976.
30. Wang M-Y, Yan H, Shi Z etal. Glucagon receptor antibody suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc Natl Acad Sci USA 2015; 112: 2503-2504.
31. Ohneda A, Ishii S, Horigome K, Yamagata S. Glucagon response to arginine after treatment of diabetes mellitus. Diabetes 1975; 24: 811-819.
32. Kawamori R, Schichiri M, Kikuchi M, Yamasaki Y, Abe H. Perfect normalization of excessive glucagon responses to intravenous arginine in human diabetes mellitus with the artificial beta-cell. Diabetes 1980; 29: 762-765.
33. Paolisso G, Sgambato S, Torella R etal. Pulsatile insulin delivery is more efficient than continuous infusion in modulating islet cell function in normal subjects and patients with type-1 diabetes. J Clin Endocrinol Metab 1988; 66: 1220-1226.
34. Cooperberg BA, Cryer PE. β-cell-mediated signalling predominates over direct α-cell signalling in the regulation of glucagon secretion in humans. Diabetes Care 2009; 32: 2275-2280.
35. Østergard T, Degn C, Gall M-A etal. The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency. J Clin Endocrinol Metab 2004; 89: 297-302.
36. Ahren B, Foley JE, Ferrannini E etal. Changes in plasma glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 2010; 33: 730-732.
37. Lanstedt-Hallin L, Adamson U, Lins PE. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycaemia in patients with type 2 diabetes. J Clin Endocrinol Metab 1999; 84: 3140-3145.
38. Rorsman P, Ramracheya R, Rorsman NJG, Zhang Q. ATP-regulated potassium channels and voltage-gated calcium channels in pancreatic alpha and beta cells: similar functions but reciprocal effects on secretion. Diabetologia 2014; 57: 1749-1761.
39. ATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. Cell Metab 2013; 18: 871-882.
40. Carpentier JL, Luyckx AS, Lefèbvre PJ. Influence of metformin on arginine-induced glucagon secretion in human diabetes. Diabete Metab 1975; 1: 23-28.
41. 13C-glucose. Effect of butylbiguanide therapy in obese mildly diabetic subjects. Diabetologia 1978; 14: 39-45.
42. Miller RA, Chu Q, Xie J etal. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013; 494: 256-260.
43. Nauck M, Meier J. Incretin-based therapies. In: Ferrannini E, Zimmet P, DeFronzo R, Alberti G, eds. International Textbook of Diabetes Mellitus. Oxford: Wiley, 2015, in press.
44. Hare KJ, Visboll T, Asmar M etal. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 2010; 59: 1765-1770.
45. DeFronzo RA, Okerson T, Viswanatha P etal. Effect of exenatide versus sitagliptine on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008; 24: 2943-2952.
46. Kolterman OG, Buse JB, Fineman MS etal. Synthetic exendin-4 (exenatide) significantly reduces poetprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-3089.
47. Degn KB, Juhl CB, Sturis J etal. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187-1194.
48. Zinman B, Gerich J, Buse JB etal. Efficacy and safety of the human glucagon-like peptide-1 liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1124-1130.
49. de Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 2008; 51: 2263-2270.
50. Rutter GA. Regulating glucagon secretion: somatostatin in the spotlight. Diabetes 2009; 58: 299-301.
51. Hauge-Evans AC, King AJ, Carmignac D etal. Somatostatin secreted by islet δ-cells fulfils multiple roles as a paracrine regulator of islet function. Diabetes 2009; 58: 403-411.
52. Meier JJ. GLP-1 receptor agonists for individualized treatment of type-2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728-742.
53. Scheen AJ. A review of gliptins for 2014. Expert Opin Pharmacother 2015; 16: 43-62.
54. Farngren J, Persson M, Schweizer A, Foley JE, Ahrén B. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycaemia in type 1 diabetes. J Clin Endocrinol Metab 2012; 97: 3799-3806.
55. Zhang MY, Yang JH, Shan CY etal. Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report. Cardiovasc Diabetol 2013; 12: 73.
56. Arakawa M, Ebato C, Mita T etal. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism 2008; 58: 1299-1306.
57. Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab 2014; 20: 573-591.
58. Krätzner R, Fröhlich F, Lepler K etal. A peroxisome proliferator-activated receptor γ-retinoid X receptor heterodimer physically interacts with the transcriptional activator PAX6 to inhibit glucagon gene transcription. Mol Pharmacol 2008; 73: 506-517.
59. Scheen AJ, Paquot N. Metabolic effects of SGLT2 inhibitors beyond increased glycosuria: a review of the clinical experience. Diabetes Metab 2014; 40: S4-11.
60. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015; 75: 33-59.
61. Ferrannini E, Muscelli E, Frascerra S etal. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124: 499-508.
62. Bonner C, Kerr-Conte J, Gmyr V etal. Glucose transporter SGLT2 inhibition triggers glucagon secretion in alpha cells (abstract). Diabetologia 2014; 57(Suppl. 1): 251.
63. Sørensen H, Brand CL, Neschen S etal. Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes 2006; 55: 2843-2848.
64. Sloop KW, Cao JX, Siesky AM etal. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotides inhibitors. J Clin Invest 2004; 113: 1571-1581.
65. Bagger JI, Knop FK, Holst JJ, Visbøll T. Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes Obes Metab 2011; 13: 965-971.
66. McShane LM, Franklin ZJ, O'Harte FP, Irwin N. Ablation of glucagon receptor signalling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice. Peptides 2014; 60: 95-101.
67. O'Harte FP, Franklin ZJ, Irwin N. Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice. Diabetes Obes Metab 2014; 16: 1214-1222.
68. Shen DM, Zhang F, Brady EJ etal. Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists. Bioorg Med Chem Lett 2005; 15: 4564-4569.
69. Mu J, Jiang G, Brady E etal. Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice. Diabetologia 2011; 54: 2381-2391.
70. Ling A, Hong Y, Gonzalez J etal. Identification of alkylidene hydrazides as glucagon receptor antagonists. J Med Chem 2001; 44: 3141-3149.
71. Ling A, Plewe M, Gonzalez J etal. Human glucagon receptor antagonists based on alkylidene hydrazides. Bioorg Med Chem Lett 2002; 12: 663-666.
72. Madsen P, Ling A, Plewe M etal. Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid[1-(2, 3, 5, 6-tetramethylbenzyl)1H-indol-4-ylmethylene]hydrazide. J Biol Chem 2002; 45: 5755-5775.
73. Lau J, Behrens C, Sidelman UG etal. New beta-alanine derivatives are orally available glucagon receptor antagonists. J Biol Chem 2007; 50: 113-128.
74. Hasegawa F, Niidome K, Migihashi C etal. Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists. Bioorg Med Chem Lett 2014; 24: 4266-4270.
75. Petersen KF, Sullivan JT. Effect of a novel glucagon receptor antagonist (BAY 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 2001; 44: 2018-2024.
76. Kelly RP, Garhyan P, Raddad E etal. Short-term administration of the glucagon receptor antagonist LY2402091 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab 2015; 17: 414-422.
77. Cryer PE. The barrier of hypoglycaemia in diabetes. Diabetes 2008; 57: 3169-3176.
78. Ali S, Drucker DJ. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab 2009; 296: E415-421.
79. Tiengo A, Nosadini R. Glucagon and lipoprotein metabolism. In: Lefèbvre PJ, ed. Glucagon II (Handbook of Experimental Pharmacology). Berlin: Springer, 1983; 441-451.
80. Guettet C, Rostaqui N, Mathe D, Lecuyer B, Navarro N, Jacotot B. Effect of chronic glucagon administration on lipoprotein composition in normally fed, fasted and cholesterol-fed rats. Lipids 1991; 26: 451-458.
81. Longuet C, Sinclair EM, Malda A. The glucagon receptor is required for adaptive metabolic response to fasting. Cell Metab 2008; 8: 359-371.
82. Sinclair EM, Yusta B, Streurker C etal. Glucagon receptor signalling is essential for control of murine hepatocyte survival. Gastroenterology 2008; 135: 2096-2106.
83. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils and pathological pitfalls. Diabetes 2013; 62: 3316-3323.
84. Parnaud G, Bosco D, Berney T etal. Proliferation of sorted human and rat beta cells. Diabetologia 2008; 51: 91-100.
85. Day JW, Ottaway N, Patterson JT etal. A new glucagon and GLP-1 coagonist eliminates obesity in rodents. Nat Chem Biol 2009; 5: 749-757.
86. Finan B, Yang B, Ottaway N etal. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 2015; 21: 27-36.
87. Arafat AM, Kaczmarek P, Skrzypski M etal. Glucagon regulates orexin A secretion in humans and rodents. Diabetologia 2014; 57: 2108-2116.
88. Scheen AJ, Paquot N. A new paradigm for treating obesity and diabetes mellitus. Nat Rev Endocrinol 2015; 11: 196-198.
89. Tan TM, Field BC, McCullough KA etal. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 2013; 62: 1131-1138.
90. Cegla J, Troke RC, Jones B etal. Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes 2014; 63: 3711-3720.